Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAP4K1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP4K1 Active Kinase Domain / K46R Kinase-Dead Mutant High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MAP4K1 Products |
| Gene Delivery | MAP4K1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MAP4K1 Products |
| Benchmark Ab | Anti-MAP4K1 Recombinant Antibody Recombinant positive control for assay validation. |
View MAP4K1 Products |
| Validator | MAP4K1 siRNA Set For knockdown verification. |
View MAP4K1 Products |
| Related Target A | PDCD1 (PD-1) Synergistic checkpoint pathway partner for combination therapies. |
View PDCD1 Products |
| Related Target B | MAP4K3 (GLK) Critical off-target homolog for kinase selectivity screening. |
View MAP4K3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (Off-target MAP4K family) | Homolog panel proteins (MAP4K3, MAP4K5) strictly verified by mass spectrometry and sequence analysis. |
| TCR Pathway Cellular Assay | Lentivirus Premade Particles for stable reporter cell line generation to capture native intracellular signaling. |
| Lack of Negative Controls | Kinase-dead mutant (K46R) recombinant protein included for background subtraction. |
| False Positives in Screening | Validated siRNA included for target-specific knockdown checks. |
Live MAP4K1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP4K1 (HPK1) therapeutics is intensifying, with major players shifting focus from traditional mAbs to highly selective small molecule inhibitors and PROTAC degraders. As first-generation therapies reach the clinic, the next wave of R&D is targeting synergistic combination strategies and overcoming systemic toxicity associated with pan-kinase inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Nimbus Therapeutics, Pfizer, BeiGene | Advanced Solid Tumors | Kinase Selectivity Assay (Need active MAP4K1 vs MAP4K3/5 proteins) |
| PROTAC / Degraders | Arvinas, Cullgen | Refractory Solid Tumors | Cellular degradation assay (Need MAP4K1-overexpressing stable cell lines via Lentivirus) |
| Combination Therapy | Bristol Myers Squibb, Roche | PD-1 Resistant Tumors | T-cell activation assays (Need functional benchmark controls and PDCD1 reagents) |